BIO-Europe Spring® 2014: Pharma steps up early on relevance data

March 27, 2014
For valuations on biotech/pharma deals, one principle has been inviolate: later stage programs, especially those demonstrating clinical Proof of Concept (PoC), are typically worth substantially more than pre-PoC programs to pharma buyers. The good news for biotech is that the last two years have seen a 180-degree turn. Proof of Relevance (PoR) has now nearly displaced PoC as the primary valuation driver for deals across discovery and development stages. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/482
Previous Video
BIO-Europe Spring® 2014: Go big or go home: When to go against the trends in R&D and dealmaking
BIO-Europe Spring® 2014: Go big or go home: When to go against the trends in R&D and dealmaking

Every pharma company boasts about being innovation-driven, yet most of their R&D targets and approaches are...

Next Video
BIO-Europe Spring® 2014: The personalized therapy challenge
BIO-Europe Spring® 2014: The personalized therapy challenge

Very few companies have the in-house expertise to understand and identify all of the relevant biomarkers re...